Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) shares were up 9.7% during mid-day trading on Thursday . The stock traded as high as $13.39 and last traded at $13.44. Approximately 455,832 shares changed hands during trading, a decline of 65% from the average daily volume of 1,298,486 shares. The stock had previously closed at $12.25.
Ginkgo Bioworks Stock Up 12.9 %
The stock’s 50-day moving average is $10.08. The company has a market capitalization of $795.24 million, a PE ratio of -1.06 and a beta of 1.09.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Palumbo Wealth Management LLC purchased a new stake in Ginkgo Bioworks in the fourth quarter worth $144,000. Forbes J M & Co. LLP raised its stake in shares of Ginkgo Bioworks by 461.4% during the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company’s stock valued at $6,891,000 after purchasing an additional 576,732 shares during the period. KBC Group NV purchased a new stake in Ginkgo Bioworks during the 4th quarter worth about $31,000. SG Americas Securities LLC bought a new position in Ginkgo Bioworks in the 4th quarter worth about $199,000. Finally, FNY Investment Advisers LLC grew its holdings in Ginkgo Bioworks by 125.6% during the 4th quarter. FNY Investment Advisers LLC now owns 75,966 shares of the company’s stock valued at $745,000 after buying an additional 42,298 shares in the last quarter. Institutional investors own 78.63% of the company’s stock.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Recommended Stories
- Five stocks we like better than Ginkgo Bioworks
- Stock Analyst Ratings and Canadian Analyst Ratings
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- What is the S&P 500 and How It is Distinct from Other Indexes
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Top Stocks Investing in 5G Technology
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
